Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis

Orsini, 2015, Amyotrophic lateral sclerosis: new perpectives and update, Neurol. Int., 7, 10.4081/ni.2015.5885 Hardiman, 2017, Amyotrophic lateral sclerosis, Nature Rev. Disease Prim., 3, 17071, 10.1038/nrdp.2017.71 Oskarsson, 2018, Amyotrophic lateral sclerosis: an update for 2018, 1617 Ragagnin, 2019, Motor neuron susceptibility in ALS/FTD, Front. Neurosci., 13, 532, 10.3389/fnins.2019.00532 Chia, 2018, Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications, Lancet Neurol., 17, 94, 10.1016/S1474-4422(17)30401-5 Bonafede, 2017, ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles, Front. Cell. Neurosci., 11, 80, 10.3389/fncel.2017.00080 Rosenfeld, 2015, Challenges in the understanding and treatment of amyotrophic lateral sclerosis/motor neuron disease, Neurotherapeutics, 12, 317, 10.1007/s13311-014-0332-8 Petrov, 2017, ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?, Front. Aging Neurosci., 9, 68, 10.3389/fnagi.2017.00068 Mazibuko, 2015, A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders, J. Pharmacol. Sci., 104, 1213, 10.1002/jps.24322 Hajipour, 2017, Advances in alzheimer's diagnosis and therapy: the implications of nanotechnology, Trends Biotechnol., 35, 937, 10.1016/j.tibtech.2017.06.002 Barcia, 2017, Nanotechnology-based drug delivery of ropinirole for Parkinson's disease, Drug Deliv., 24, 1112, 10.1080/10717544.2017.1359862 Tsou, 2017, Drug delivery to the brain across the blood–brain barrier using nanomaterials, Small, 13, 10.1002/smll.201701921 Hu, 2016, Targeting the blood-spinal cord barrier: a therapeutic approach to spinal cord protection against ischemia-reperfusion injury, Life Sci., 158, 1, 10.1016/j.lfs.2016.06.018 Abbott, 2013, Blood–brain barrier structure and function and the challenges for CNS drug delivery, J. Inherit. Metab. Dis., 36, 437, 10.1007/s10545-013-9608-0 Sharma, 2016, ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function, Nat. Commun., 7, 10465, 10.1038/ncomms10465 Soto, 2018, Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases, Nat. Neurosci., 1 Chou, 2018, TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD, Nat. Neurosci., 21, 228, 10.1038/s41593-017-0047-3 Howland, 2002, Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS), Proc. Natl. Acad. Sci. U. S. A., 99, 1604, 10.1073/pnas.032539299 Carrì, 2015, Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS, Front. Cell. Neurosci., 9, 41 Lall, 2017, Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia, J. Clin. Invest., 127, 3250, 10.1172/JCI90607 Morello, 2017, Neuroinflammation and ALS: transcriptomic insights into molecular disease mechanisms and therapeutic targets, Mediat. Inflamm., 2017, 10.1155/2017/7070469 Burk, 2019, Disrupted neuronal trafficking in amyotrophic lateral sclerosis, Acta Neuropathol., 1 McMahon, 2017, Gene therapy: gene-editing therapy for neurological disease, Nat. Rev. Neurol., 13, 7, 10.1038/nrneurol.2016.190 Dharmadasa, 2018, Riluzole, disease stage and survival in ALS, Lancet Neurol., 17, 385, 10.1016/S1474-4422(18)30091-7 Rothstein, 2017, Edaravone: a new drug approved for ALS, Cell, 171, 725, 10.1016/j.cell.2017.10.011 Lu, 2016, Current therapy of drugs in amyotrophic lateral sclerosis, Curr. Neuropharmacol., 14, 314, 10.2174/1570159X14666160120152423 Cinzia, 2019, Histamine beyond its effects on allergy: potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS), Pharmacol. Ther., 202, 120, 10.1016/j.pharmthera.2019.06.006 Furtado, 2018, Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases, Adv. Mater., 30, 10.1002/adma.201801362 Lovejoy, 2014, The potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosis, Front. Aging Neurosci., 6, 173, 10.3389/fnagi.2014.00173 Urbi, 2019, Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial, BMJ open, 9, 10.1136/bmjopen-2019-029449 Funke, 2018, Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach, Amyotroph Lateral Scler Frontotemporal Degener, 19, 342, 10.1080/21678421.2018.1431786 Al-Chalabi, 2019, Potential of the cardiovascular drug levosimendan in the management of amyotrophic lateral sclerosis: an overview of a working hypothesis, J. Cardiovasc. Pharmacol., 74, 389, 10.1097/FJC.0000000000000728 Gold, 2019, Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial, Amyotroph Lateral Scler Frontotemporal Degener, 20, 595, 10.1080/21678421.2019.1632899 Vucic, 2020, Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): study protocol clinical trial (SPIRIT Compliant), Medicine (Baltimore), 99, 10.1097/MD.0000000000018904 Chiò, 2020, Disease-Modifying therapies in amyotrophic lateral sclerosis, Neuropharmacology, 107986, 10.1016/j.neuropharm.2020.107986 Chidambaram, 2020, Mitochondria-targeted drug delivery in neurodegenerative diseases, 97 Kumar, 2020, Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice, ACS Omega, 5, 2345, 10.1021/acsomega.9b03735 Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 Zheng, 2018, Nanotechnology-based strategies for siRNA brain delivery for disease therapy, Trends Biotechnol., 36, 562, 10.1016/j.tibtech.2018.01.006 Garbuzova-Davis, 2014, Blood-CNS barrier impairment in ALS patients versus an animal model, Front. Cell. Neurosci., 8, 21, 10.3389/fncel.2014.00021 Sweeney, 2018, Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders, Nat. Rev. Neurol., 14, 133, 10.1038/nrneurol.2017.188 Chen, 2012, Modern methods for delivery of drugs across the blood–brain barrier, Adv. Drug Deliv. Rev., 64, 640, 10.1016/j.addr.2011.11.010 Löscher, 2005, Drug resistance in brain diseases and the role of drug efflux transporters, Nat. Rev. Neurosci., 6, 591, 10.1038/nrn1728 Jablonski, 2012, Selective increase of two ABC drug efflux transporters at the blood–spinal cord barrier suggests induced pharmacoresistance in ALS, Neurobiol. Dis., 47, 194, 10.1016/j.nbd.2012.03.040 Aryal, 2017, Effects on P-glycoprotein expression after blood-brain barrier disruption using focused ultrasound and microbubbles, PloS One, 12, 10.1371/journal.pone.0166061 Abrahao, 2019, First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound, Nat. Commun., 10, 1, 10.1038/s41467-019-12426-9 Grabrucker, 2016, Nanoparticle transport across the blood brain barrier, Tissue Barriers, 4, 10.1080/21688370.2016.1153568 Savjani, 2012, Drug solubility: importance and enhancement techniques, ISRN Pharm., 2012 Bordet, 2010, Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound, Pharmaceuticals, 3, 345, 10.3390/ph3020345 Tesla, 2012, Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis, Proc. Natl. Acad. Sci. U. S. A., 109, 17016, 10.1073/pnas.1213960109 Limpert, 2013, Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS), Beilstein J. Org. Chem., 9, 717, 10.3762/bjoc.9.82 Banks, 2009, Characteristics of compounds that cross the blood-brain barrier, S3 Foust, 2013, Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS, Mol. Ther., 21, 2148, 10.1038/mt.2013.211 Kadam, 2012, Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance, Drug Metab. Dispos., 40, 1380, 10.1124/dmd.112.044925 Nau, 2010, Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections, Clin. Microbiol. Rev., 23, 858, 10.1128/CMR.00007-10 ud Din, 2017, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int. J. Nanomed., 12, 7291, 10.2147/IJN.S146315 Sharma, 2016, Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs, Sci. Tech. Rep., 2016 Dash, 2018, Two decades-long journey from Riluzole to Edaravone: revisiting the clinical pharmacokinetics of the only two amyotrophic lateral sclerosis therapeutics, Clin. Pharmacokinet., 57, 1385, 10.1007/s40262-018-0655-4 Li, 2017, Cancer drug delivery in the nano era: an overview and perspectives, Oncol. Rep., 38, 611, 10.3892/or.2017.5718 Saraiva, 2016, Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases, J. Contr. Release, 235, 34, 10.1016/j.jconrel.2016.05.044 Gastaldi, 2014, Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art, Eur. J. Pharm. Biopharm., 87, 433, 10.1016/j.ejpb.2014.05.004 Tosi, 2013, Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier, Curr. Med. Chem., 20, 2212, 10.2174/0929867311320170006 Shilo, 2015, The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model, J. Nanobiotechnol., 13, 19, 10.1186/s12951-015-0075-7 Mishra, 2016, Dendrimer technologies for brain tumor, Drug Discov. Today, 21, 766, 10.1016/j.drudis.2016.02.006 Monaco, 2014, Carbon-based smart nanomaterials in biomedicine and neuroengineering, Beilstein J. Nanotechnol., 5, 1849, 10.3762/bjnano.5.196 Zou, 2018, Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine, Adv. Mater., 30, 1803717, 10.1002/adma.201803717 Kou, 2018, Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery, Expet Opin. Drug Deliv., 15, 869, 10.1080/17425247.2018.1517749 Ochs, 2000, A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis, Amyotroph Lateral Scler., 1, 201 Miller, 2013, A phase I, randomised, first-in-human study of an antisense oligonucleotide directed against SOD1 delivered intrathecally in SOD1-familial ALS patients, Lancet Neurol., 12, 435, 10.1016/S1474-4422(13)70061-9 Lunn, 2014, Concise review: stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future, Stem Cell., 32, 1099, 10.1002/stem.1628 Huang, 2019, Nanotherapeutic strategies for the treatment of neurodegenerative diseases, 321 Householder, 2019, Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice, Sci. Rep., 9, 1, 10.1038/s41598-019-49028-w Chung, 2020, Targeting small molecule delivery to the brain and spinal cord via intranasal administration of rabies virus glycoprotein (RVG29)-Modified PLGA nanoparticles, Pharmaceutics, 12, 93, 10.3390/pharmaceutics12020093 Spinelli, 2019, Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long-lasting stability, J. Nanobiotechnol., 17, 49, 10.1186/s12951-019-0481-3 Klim, 2019, ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair, Nat. Neurosci., 22, 167, 10.1038/s41593-018-0300-4 Sahoo, 2017, Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging, Nanomed. Cancer, Pan Stanford, 73 Wang, 2011, More effective nanomedicines through particle design, Small, 7, 1919, 10.1002/smll.201100442 Sawada, 2017, Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis, Expet Opin. Pharmacother., 18, 735, 10.1080/14656566.2017.1319937 Choi, 2007, Renal clearance of nanoparticles, Nat. Biotechnol., 25, 1165, 10.1038/nbt1340 Agrawal, 2014, Is nanotechnology a boon for oral drug delivery?, Drug Discov. Today, 19, 1530, 10.1016/j.drudis.2014.04.011 Bourquin, 2018, Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials, Adv. Mater., 30, 1704307, 10.1002/adma.201704307 Zhou, 2018, Crossing the blood-brain barrier with nanoparticles, J. Contr. Release, 270, 290, 10.1016/j.jconrel.2017.12.015 Kamaly, 2016, Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release, Chem. Rev., 116, 2602, 10.1021/acs.chemrev.5b00346 Bao, 2018, Simultaneous blood–brain barrier crossing and protection for stroke treatment based on edaravone-loaded ceria nanoparticles, ACS Nano, 12, 6794, 10.1021/acsnano.8b01994 Morachis, 2012, Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles, Pharmacol. Rev., 64, 505, 10.1124/pr.111.005363 Leriche, 2012, Cleavable linkers in chemical biology, Bioorg. Med. Chem., 20, 571, 10.1016/j.bmc.2011.07.048 Chang, 2016, Smart linkers in polymer–drug conjugates for tumor-targeted delivery, J. Drug Target., 24, 475, 10.3109/1061186X.2015.1108324 Zhang, 2019, Recent advances in stimuli-responsive polymer systems for remotely controlled drug release, Prog. Polym. Sci., 101164, 10.1016/j.progpolymsci.2019.101164 Nabi, 2020, Riluzole loaded nanoparticles to alleviate the symptoms of neurological disorders by attenuating oxidative stress, Drug Dev. Ind. Pharm., 1 Ma, 2013, Gold nanoshell nanomicelles for potential magnetic resonance imaging, light-triggered drug release, and photothermal therapy, Adv. Funct. Mater., 23, 815, 10.1002/adfm.201201663 Zheng, 2019, ROS-Responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy, Adv. Mater., 31, 1903277, 10.1002/adma.201903277 Liu, 2019, Switchable nanoparticle for programmed gene-chem delivery with enhanced neuronal recovery and CT imaging for neurodegenerative disease treatment, Mater. Horiz., 6, 1923, 10.1039/C9MH00482C Sirsi, 2014, State-of-the-art materials for ultrasound-triggered drug delivery, Adv. Drug Deliv. Rev., 72, 3, 10.1016/j.addr.2013.12.010 Barber, 2010, Oxidative stress in ALS: key role in motor neuron injury and therapeutic target, Free Radic. Biol. Med., 48, 629, 10.1016/j.freeradbiomed.2009.11.018 Silva Adaya, 2017, Nanobiomaterials' applications in neurodegenerative diseases, J. Biomater. Appl., 31, 953, 10.1177/0885328216659032 Mathew, 2012, Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease, PloS One, 7, 10.1371/journal.pone.0032616 Rogers, 2014, Non-viral gene therapy that targets motor neurons in vivo, Front. Mol. Neurosci., 7, 80, 10.3389/fnmol.2014.00080 Kwon, 2016, Neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries, ACS Nano, 10, 7926, 10.1021/acsnano.6b03858 Posse de Chaves, 2010, Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction, FEBS Lett., 584, 1748, 10.1016/j.febslet.2009.12.010 Sheikh, 2016, Antibody-based neuronal and axonal delivery vectors for targeted ligand delivery, Neural Regen. Res., 11, 712, 10.4103/1673-5374.182685 Sellers, 2016, Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration, Proc. Natl. Acad. Sci. U. S. A., 113, 2514, 10.1073/pnas.1515526113 Yamanaka, 2018, The multi-dimensional roles of astrocytes in ALS, Neurosci. Res., 126, 31, 10.1016/j.neures.2017.09.011 Gu, 2017, Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes, Drug Deliv. Transl. Res., 7, 497, 10.1007/s13346-017-0368-5 Gromnicova, 2013, Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro, PloS One, 8, 10.1371/journal.pone.0081043 Surnar, 2018, Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection, Proc. Natl. Acad. Sci. U. S. A., 115, E12333, 10.1073/pnas.1816429115 Shimoni, 2016, Delivery of fluorescent nanoparticles to the brain, J. Mol. Neurosci., 60, 405, 10.1007/s12031-016-0833-5 Koffie, 2011, Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging, Proc. Natl. Acad. Sci. U. S. A., 108, 18837, 10.1073/pnas.1111405108 Shi, 2017, Multifunctional hybrid nanoparticles for traceable drug delivery and intracellular microenvironment-controlled multistage drug-release in neurons, Small, 13, 1603966, 10.1002/smll.201603966 Wu, 2010, Novel magnetic hydroxyapatite nanoparticles as non-viral vectors for the glial cell line-derived neurotrophic factor gene, Adv. Funct. Mater., 20, 67, 10.1002/adfm.200901108 Minami, 2012, Selective targeting of microglia by quantum dots, J. Neuroinflammation, 9, 22, 10.1186/1742-2094-9-22 Lin, 2018, Graphene-based nanomaterials in bioimaging, 247 Nicolas, 2013, Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery, Chem. Soc. Rev., 42, 1147, 10.1039/C2CS35265F Fu, 2017, A versatile upconversion surface evaluation platform for bio–nano surface selection for the nervous system, Nanoscale, 9, 13683, 10.1039/C7NR03557H Liu, 2019, Switchable nanoparticle for programmed gene-chem delivery with enhanced neuronal recovery and CT imaging for neurodegenerative disease treatment, Mater. Horiz., 6, 1923, 10.1039/C9MH00482C Blasco, 2014, The glutamate hypothesis in ALS: pathophysiology and drug development, Curr. Med. Chem., 21, 3551, 10.2174/0929867321666140916120118 Zarei, 2015, A comprehensive review of amyotrophic lateral sclerosis, Surg. Neurol. Int., 6, 10.4103/2152-7806.169561 Rizzo, 2014, Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis, Cell. Mol. Life Sci., 71, 999, 10.1007/s00018-013-1480-4 Verma, 2016, Enhancement in the neuroprotective power of riluzole against cerebral ischemia using a brain targeted drug delivery vehicle, ACS Appl. Mater. Interfaces, 8, 19716, 10.1021/acsami.6b01776 Bondì, 2010, Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution, Nanomedicine, 5, 25, 10.2217/nnm.09.67 Rao, 2015, Designing novel nanoformulations targeting glutamate transporter excitatory amino acid transporter 2: implications in treating drug addiction, J. Personalized Med., 1, 3 File, 2012, Summary of ceftaroline fosamil clinical trial studies and clinical safety, Clin. Infect. Dis., 55, S173, 10.1093/cid/cis559 Kumar, 2016, Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers, Chem. Phys. Lipids, 200, 126, 10.1016/j.chemphyslip.2016.09.002 Benkler, 2016, Multifactorial gene therapy enhancing the glutamate uptake system and reducing oxidative stress delays symptom onset and prolongs survival in the SOD1-G93A ALS mouse model, J. Mol. Neurosci., 58, 46, 10.1007/s12031-015-0695-2 Wong, 2017, Will nanotechnology bring new hope for gene delivery?, Trends Biotechnol., 35, 434, 10.1016/j.tibtech.2016.12.009 Li, 2017, Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice, ACS Nano, 11, 95, 10.1021/acsnano.6b04261 Valiante, 2015, Peptide gh625 enters into neuron and astrocyte cell lines and crosses the blood–brain barrier in rats, Int. J. Nanomed., 10, 1885 Terashima, 2018, Gene therapy for neuropathic pain through siRNA-IRF5 gene delivery with homing peptides to microglia, Mol. Ther. Nucleic Acids, 11, 203, 10.1016/j.omtn.2018.02.007 Valori, 2019, Astrocytes: emerging therapeutic targets in neurological disorders, Trends Mol. Med., 25, 750, 10.1016/j.molmed.2019.04.010 Jin, 2017, Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability, Theranostics, 7, 884, 10.7150/thno.18219 Yang, 2018, Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: a potent approach to treat amyotrophic lateral sclerosis, Eur. J. Pharmaceut. Sci., 120, 30, 10.1016/j.ejps.2018.04.026 Moujalled, 2016, Advances in the development of disease-modifying treatments for amyotrophic lateral sclerosis, CNS Drugs, 30, 227, 10.1007/s40263-016-0317-8 Wei, 2013, Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes, Chem. Soc. Rev., 42, 6060, 10.1039/c3cs35486e Wu, 2019, Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II), Chem. Soc. Rev., 48, 1004, 10.1039/C8CS00457A DeCoteau, 2016, Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis, Nanomed. Nanotechnol. Biol. Med., 12, 2311, 10.1016/j.nano.2016.06.009 Zhao, 2013, Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis, J. Neuroimmune Pharmacol., 8, 888, 10.1007/s11481-013-9489-x Sun, 2019, Synthesis and characterization of a silica-based drug delivery system for spinal cord injury therapy, Nano-Micro Lett., 11, 23, 10.1007/s40820-019-0252-6 Khalid, 2017, Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials, Front. Neurol., 8, 486, 10.3389/fneur.2017.00486 Kiaei, 2006, Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis, J. Neurosci., 26, 2467, 10.1523/JNEUROSCI.5253-05.2006 Tripodo, 2015, Mesenchymal stromal cells loading curcumin-INVITE-micelles: a drug delivery system for neurodegenerative diseases, Colloids Surf., B, 125, 300, 10.1016/j.colsurfb.2014.11.034 Ward, 2015, Neurodegenerative diseases and therapeutic strategies using iron chelators, J. Trace Elem. Med. Biol., 31, 267, 10.1016/j.jtemb.2014.12.012 Bonda, 2012, Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming!, CNS Neurol. Disord. - Drug Targets, 11, 81, 10.2174/187152712799960709 Liu, 2006, Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance, Neurosci. Lett., 406, 189, 10.1016/j.neulet.2006.07.020 Chen, 2018, Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy, Adv. Mater., 30, 1703458, 10.1002/adma.201703458 Di Carlo, 2012, Are oxidative stress and mitochondrial dysfunction the key players in the neurodegenerative diseases?, Free Radic. Res., 46, 1327, 10.3109/10715762.2012.714466 Wen, 2016, Nanotechnology inspired tools for mitochondrial dysfunction related diseases, Adv. Drug Deliv. Rev., 99, 52, 10.1016/j.addr.2015.12.024 Kwon, 2018, Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson's disease, Angew. Chem. Int. Ed., 57, 9408, 10.1002/anie.201805052 Kwon, 2016, Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer's disease, ACS Nano, 10, 2860, 10.1021/acsnano.5b08045 Fischer, 2010, SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse, Brain, 134, 196, 10.1093/brain/awq314 Reddy, 2008, Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress, Appl. Biochem. Biotechnol., 151, 565, 10.1007/s12010-008-8232-1 Lee, 2015, Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key?, Exp. Neurobiol., 24, 1, 10.5607/en.2015.24.1.1 Taylor, 2016, Decoding ALS: from genes to mechanism, Nature, 539, 197, 10.1038/nature20413 Scotter, 2015, TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets, Neurotherapeutics, 12, 352, 10.1007/s13311-015-0338-x Ratti, 2016, Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins, J. Neurochem., 138, 95, 10.1111/jnc.13625 Becker, 2017, Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice, Nature, 544, 367, 10.1038/nature22038 O'Connor, 2015, Gene therapy for neurodegenerative diseases, Trends Mol. Med., 21, 504, 10.1016/j.molmed.2015.06.001 Manabe, 2002, Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis, Apoptosis, 7, 329, 10.1023/A:1016123413038 Suzuki, 2016, Ex vivo gene therapy using human mesenchymal stem cells to deliver growth factors in the skeletal muscle of a familial ALS rat model, 325 Reddy, 2015, RNA-targeted therapeutics for ALS, Neurotherapeutics, 12, 424, 10.1007/s13311-015-0344-z Rezaee, 2016, Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems, J. Contr. Release, 236, 1, 10.1016/j.jconrel.2016.06.023 Scarrott, 2015, Current developments in gene therapy for amyotrophic lateral sclerosis, Expet Opin. Biol. Ther., 15, 935, 10.1517/14712598.2015.1044894 Chen, 2016, Production and clinical development of nanoparticles for gene delivery, Mol. Ther. Methods Clin. Dev., 3, 16023, 10.1038/mtm.2016.23 Chen, 2017, Improving the delivery of SOD1 antisense oligonucleotides to motor neurons using calcium phosphate-lipid nanoparticles, Front. Neurosci., 11, 476, 10.3389/fnins.2017.00476 Guo, 2019, Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳ s disease, Acta Pharm. Sin. B, 9, 590, 10.1016/j.apsb.2018.12.010 Shruthi, 2017, Brain-derived neurotrophic factor facilitates functional recovery from ALS-cerebral spinal fluid-induced neurodegenerative changes in the NSC-34 motor neuron cell line, Neurodegener. Dis., 17, 44, 10.1159/000447559 Tan, 2012, Nanoporous peptide particles for encapsulating and releasing neurotrophic factors in an animal model of neurodegeneration, Adv. Mater., 24, 3362, 10.1002/adma.201200634 Chung, 2017, Brain-derived neurotrophic factor loaded PS80 PBCA nanocarrier for in vitro neural differentiation of mouse induced pluripotent stem cells, Int. J. Mol. Sci., 18, 663, 10.3390/ijms18030663 Kanwar, 2012, Neurological disorders and therapeutics targeted to surmount the blood–brain barrier, Int. J. Nanomed., 7, 3259, 10.2147/IJN.S30919 Khalin, 2016, Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury, Drug Deliv., 23, 3520, 10.1080/10717544.2016.1199609 Millecamps, 2013, Axonal transport deficits and neurodegenerative diseases, Nat. Rev. Neurosci., 14, 161, 10.1038/nrn3380 Marinković, 2012, Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis, Proc. Natl. Acad. Sci. U. S. A., 109, 4296, 10.1073/pnas.1200658109 Fischer, 2007, Axonal degeneration in motor neuron disease, Neurodegener. Dis., 4, 431, 10.1159/000107704 Guo, 2017, HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients, Nat. Commun., 8, 861, 10.1038/s41467-017-00911-y Yuan, 2017, Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer, Int. J. Nanomed., 12, 6503, 10.2147/IJN.S136142 El Bahhaj, 2016, Histone deacetylase inhibitors delivery using nanoparticles with intrinsic passive tumor targeting properties for tumor therapy, Theranostics, 6, 795, 10.7150/thno.13725 Goutman, 2019, Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials, Expet Opin. Invest. Drugs, 28, 525, 10.1080/13543784.2019.1627324 Deb, 2012, Nanotechnology in stem cells research: advances and applications, Front. Biosci., 17, 1747, 10.2741/4016 Wang, 2012, Towards whole-body imaging at the single cell level using ultra-sensitive stem cell labeling with oligo-arginine modified upconversion nanoparticles, Biomaterials, 33, 4872, 10.1016/j.biomaterials.2012.03.047 Vissers, 2019, Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders, Adv. Drug Deliv. Rev., 148, 239, 10.1016/j.addr.2019.02.007 Kuo, 2017, Nerve growth factor-loaded heparinized cationic solid lipid nanoparticles for regulating membrane charge of induced pluripotent stem cells during differentiation, Mater. Sci. Eng. C, 77, 680, 10.1016/j.msec.2017.03.303 Anraku, 2017, Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain, Nat. Commun., 8, 1001, 10.1038/s41467-017-00952-3 Lee, 2017, Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors, Adv. Mater., 29, 1605563, 10.1002/adma.201605563 Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J. Contr. Release, 207, 18, 10.1016/j.jconrel.2015.03.033 Andaloussi, 2013, Exosomes for targeted siRNA delivery across biological barriers, Adv. Drug Deliv. Rev., 65, 391, 10.1016/j.addr.2012.08.008 Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat. Biotechnol., 29, 341, 10.1038/nbt.1807 Kim, 2018, Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ, EBioMedicine, 28, 261, 10.1016/j.ebiom.2018.01.002 Riazifar, 2019, Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders, ACS Nano, 13, 6670, 10.1021/acsnano.9b01004 Patra, 2018, Nano based drug delivery systems: recent developments and future prospects, J. Nanobiotechnol., 16, 71, 10.1186/s12951-018-0392-8 Xu, 2015, Cancer nanomedicine: from targeted delivery to combination therapy, Trends Mol. Med., 21, 223, 10.1016/j.molmed.2015.01.001 Anselmo, 2016, Nanoparticles in the clinic, Bioeng. Transl. Med., 1, 10, 10.1002/btm2.10003 Su, 2018, Potential applications and human biosafety of nanomaterials used in nanomedicine, J. Appl. Toxicol., 38, 3, 10.1002/jat.3476 Muthu, 2012, Challenges posed by the scale-up of nanomedicines, Nanomedicine, 7, 307, 10.2217/nnm.12.3